hackint0sh/New-Dataset huggingface dataset:
* Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety. conditions: Chronic Subdural Hematoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 520 type: ESTIMATED name: Conventional Surgery name: Middle Meningeal Artery Embolization (MMAE) measure: Need for Rescue Surgery or Death measure: Safety of MMAE and Conventional Open Surgery sex: ALL minimumAge: 40 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Texas Medical Branch city: Galveston state: Texas zip: 77555 country: United States name: Study Manager role: CONTACT phone: 262-470-4293 email: jlspahn@utmb.edu name: Peter Kan, MD role: PRINCIPAL_INVESTIGATOR lat: 29.30135 lon: -94.7977 hasResults: False
nctId: NCT06347783 id: STUDY00026893 briefTitle: Automated Insulin Delivery vs. Injections: Sleep Impact in Pediatric Type 1 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-11-15 date: 2024-12-15 date: 2024-04-04 date: 2024-04-04 name: Oregon Health and Science University class: OTHER briefSummary: The purpose of the study is to learn about the effect of insulin pumps on sleep in pediatric patients with type 1 diabetes and their caregivers. We are hoping to find out if insulin pumps improve sleep, worsen sleep, or have no effect at all. We are hoping to also explore the relationship between insulin pumps, sleep, and overnight blood sugar control. Your information will not be stored and used for future research.
* Fill out daily sleep diaries over the same 2 week period. conditions: Type1diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Insulin pump measure: Sleep duration measure: Sleep efficiency measure: Sleep Disturbance Scale for Children measure: Promis Short Form 8a measure: Time in range sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Oregon Health and Science University city: Portland state: Oregon zip: 97239 country: United States name: Rachel L Palting, DO role: CONTACT phone: 503-494-1966 email: palting@ohsu.edu name: Ines Guttman-Bauman, MD role: CONTACT phone: 503-494-8509 email: Guttman@ohsu.edu name: Rachel L Palting, DO role: PRINCIPAL_INVESTIGATOR name: Ines Guttman-Bauman, MD role: SUB_INVESTIGATOR lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06347770 id: ThirdSunYat-senECII202329903 briefTitle: Effect of Probiotics Before Cesarean Section on Postoperative Recovery in Pregnant Women overallStatus: RECRUITING date: 2023-11-01 date: 2025-10 date: 2025-10 date: 2024-04-04 date: 2024-04-08 name: Third Affiliated Hospital, Sun Yat-Sen University class: OTHER briefSummary: This study aims to evaluate the effect of probiotics 7 days before cesarean section (CS) on postoperative recovery and the change of gut microbiota in pregnant women. Samples were obtained from a total of 80 pregnant individuals, divided into control group and probiotics group. Anal exhaust time and first defecating time were set as the primary outcome of recovery of CS. 16S rRNA amplicon sequencing of the V4 region was analyzed to evaluate the composition of them. conditions: Microbiota conditions: Postoperative Recovery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 80 type: ESTIMATED name: Probiotic Blend Oral Tablet measure: analysis of postoperative recovery measure: 16S rRNA amplicon sequencing of the V4 region sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Zhe Li status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: Yiwen Zhang, MD role: CONTACT phone: +86-18145701061 lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06347757 id: NorthernJiangsuhospital1 briefTitle: A 3-Arm Study Comparing the Efficacy of Anti-Reflux Reconstruction Protocols After Laparoscopic Proximal Gastrectomy overallStatus: COMPLETED date: 2020-01-01 date: 2023-12-31 date: 2024-03-15 date: 2024-04-04 date: 2024-04-04 name: Northern Jiangsu People's Hospital class: OTHER briefSummary: The efficacy of three different alimentary reconstruction methods after proximal gastrectomy will be investigated in this study in a prospective, multicenter, randomized controlled trial. conditions: Anti-Reflux Alimentary Reconstruction conditions: Laparoscopic Proximal Gastrectomy conditions: Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 180 type: ACTUAL name: Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy measure: Incidence of reflux esophagitis measure: Incidence of anastomotic leakage measure: Incidence of anastomotic stenosis measure: Operative time measure: Intra-operative blood loss measure: Overall survival, and disease-free survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jiajie Zhou city: Yangzhou country: China lat: 32.39722 lon: 119.43583 hasResults: False
nctId: NCT06347744 id: RADX-P-2401 briefTitle: Radicle Rest 24: A Study of Health and Wellness Products on Sleep and Related Health Outcomes overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-09 date: 2024-12 date: 2024-04-04 date: 2024-04-08 name: Radicle Science class: INDUSTRY briefSummary: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on sleep and related health outcomes. conditions: Sleep conditions: Sleep Disturbance conditions: Sleep Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be stratified based on gender at birth then randomized to one of the study arms. primaryPurpose: OTHER masking: DOUBLE maskingDescription: Participants will be stratified based on gender at birth then randomized to one of the study arms whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 1200 type: ESTIMATED name: Radicle Rest Placebo Control Form 1 name: Radicle Rest Active Study Product 1.1 Usage name: Radicle Rest Placebo Control Form 2 name: Radicle Rest Active Study Product 2.1 Usage measure: Change in sleep measure: Change in feelings of anxiety measure: Change in fatigue measure: Change in mood (emotional distress-depression) measure: Minimal clinically important difference (MCID) in sleep measure: Minimal clinically important difference (MCID) in feelings of anxiety measure: Minimal clinically important difference (MCID) in fatigue measure: Minimal clinically important difference (MCID) in mood (emotional distress-depression) sex: ALL minimumAge: 21 Years maximumAge: 105 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Radicle Science, Inc city: Del Mar state: California zip: 92014 country: United States lat: 32.95949 lon: -117.26531 hasResults: False
nctId: NCT06347731 id: VAR-2024-01 briefTitle: Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-03 date: 2025-03 date: 2024-04-04 date: 2024-04-17 name: Varian, a Siemens Healthineers Company class: INDUSTRY briefSummary: This study is a clinical trial of prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 participants enrolled. All participants will be treated with radiation therapy using the medical device of Varian ProBeam360° Proton Therapy System (ProBeam360°), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration. conditions: Tumor, Solid studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: prospective, open-label, non-randomized, single-arm objective performance criteria primaryPurpose: TREATMENT masking: NONE count: 47 type: ESTIMATED name: Proton Radiation Therapy measure: Effectiveness measure: tumor disease control rate reaches the objective performance criteria (80%) measure: Safety measure: Incidence of CTCAE grade 3 toxic reaction is acceptable (lower than 5%) measure: Safety measure: Incidence of CTCAE grade 4 and 5 toxic reaction is acceptable (0%) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06347718 id: CASTLE id: 2022-001366-35 type: EUDRACT_NUMBER id: DRKS00032279 type: REGISTRY domain: Deutsches Register Klinischer Studien (DRKS) briefTitle: CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease acronym: CASTLE overallStatus: RECRUITING date: 2023-07-17 date: 2026-05-31 date: 2026-05-31 date: 2024-04-04 date: 2024-04-04 name: University of Erlangen-Nürnberg Medical School class: OTHER briefSummary: The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on the cell surface of B cells and their precursors. During treatment, patients undergo leukapheresis, lymophodepleting chemotherapy and administration of the expanded CD19-CAR-transduced T cells. conditions: Systemic Lupus Erythematosus conditions: Systemic Sclerosis conditions: Dermatomyositis conditions: Polymyositis studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Phase 1:
Evaluating the efficiency of CAR-T-Cells in systemic autoimmune diseases with 16 patients primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: anti-CD19 CAR T cell therapy measure: To assess the safety of anti-CD19 CAR T cell therapy in subjects with active B-driven autoimmune disease (SLE, SSc and DM/PM). measure: Clinical efficacy SSc measure: Clinical efficacy SLE measure: Clinical efficacy DM measure: Cellular response measure: Serological response measure: Success of IMP process measure: Physicians Global Assessment to measure quality of life measure: Patient's Global Assessment to measure quality of life measure: Health Assessment Questionnaire measure: Functional Assessment of Chronic Illness Therapy measure: SLE-specific disease activity over time per subject measure: SSc-specific disease activity over time per subject measure: DM/PM-specific disease activity over time per subject measure: SLE-specific disease activity over time per subject measure: DM/PM-specific disease activity over time per subject sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitätsklinikum Erlangen status: RECRUITING city: Erlangen state: Bavaria zip: 91054 country: Germany name: Georg Schett, Prof. Dr. role: CONTACT name: Daniela Bohr, Dr. role: CONTACT lat: 49.59099 lon: 11.00783 hasResults: False
nctId: NCT06347705 id: 23-252 briefTitle: A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer overallStatus: RECRUITING date: 2024-03-28 date: 2029-03-28 date: 2029-03-28 date: 2024-04-04 date: 2024-04-05 name: Memorial Sloan Kettering Cancer Center class: OTHER briefSummary: The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the body after treatment. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 99 type: ESTIMATED name: 2141-V11 Antibody measure: Number of participants with a complete response or minimal residual disease. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (Limited protocol activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (Limited Protocol Activities) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center (All protocol activites) status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (Limited Protocol Activites) status: RECRUITING city: Rockville Centre state: New York zip: 11553 country: United States name: Matthew Dallos, MD role: CONTACT phone: 646-888-4716 lat: 40.65871 lon: -73.64124 hasResults: False
nctId: NCT06347692 id: SCBR-240/2024 briefTitle: Effect of Antigravity Treadmill in Knee Osteoarthritis (AGTreadmill) acronym: AGTreadmill overallStatus: NOT_YET_RECRUITING date: 2024-04-07 date: 2024-04-20 date: 2025-04-20 date: 2024-04-04 date: 2024-04-04 name: Prince Sattam Bin Abdulaziz University class: OTHER briefSummary: To date, the anti-gravity treadmill, as a representative method of lower body positive pressure treadmills, has been rarely reported for knee osteoarthritis rehabilitation.
Purpose: This study aims to evaluate the effect of antigravity treadmill training on pain, gait characteristics, and function in patients with knee osteoarthritis. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study included 40 patients with knee osteoarthritis who were randomly assigned to one of two groups: the antigravity treadmill group (n=20) or the control group (n=20). For 12 weeks, the antigravity treadmill group received training on the Alter G treadmill (75% weight-bearing, 30 minutes per session, three times per week) combined with traditional physical therapy. During the same period, the control group received only traditional physical therapy. The Visual Analogue Scale, Walkway System, and the Western Ontario and McMaster Universities Arthritis Index were used to assess pain, spatiotemporal gait parameters, and patient function, respectively. All outcome measures were obtained pretreatment, post-treatment primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Patients were randomly assigned to either the antigravity treadmill group (n = 20) or the control group (n = 20 ) using an online randomization website (www.randomization.com). The control group received a conventional physical therapy program. The therapists responsible for measuring and assessing the outcomes remained blinded to the group assignments. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: antigravity treadmill name: physical therapy exercise program measure: Assessment of patient pain measure: Evaluation of gait parameters (step length) measure: Evaluation of gait parameters (step time) measure: Evaluation of gait parameters (velocity) measure: Evaluation of patient function sex: ALL minimumAge: 50 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06347679 id: WCHSIRB-CT-2024-160 briefTitle: Effects of Aromatherapy on Anxiety and Pain During Dental Treatments in Adults: a Randomized Controlled Clinical Trial overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2026-04-01 date: 2024-04-04 date: 2024-04-04 name: Sichuan University class: OTHER briefSummary: Dental anxiety is a common problem in dental care. The aim of this protocol is to evaluate the effect of orange and tea essential oil for the control of anxiety and pain in adults during dental treatments. conditions: Dental Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Aroma diffuser with single-note sweet orange essential oil name: Aroma diffuser with single-note tea tree essential oil name: Aroma diffuser with water measure: Anxiety scale 1 - Modified Dental Anxiety Scale (MDAS) measure: Pain scale - Visual Analog Scale (VAS) measure: Anxiety scale 2 - State-Trait Anxiety Inventory for State Anxiety (STAI-S) measure: Vital sign 1 - systolic blood pressure (SBP) measure: Vital sign 2 - diastolic blood pressure (DBP) measure: Vital sign 3 - heart rate (HR） measure: Vital sign 4 - oxygen saturation (SpO2） sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT hasResults: False
nctId: NCT06347666 id: 23082905 briefTitle: Coaching in Early Development Project overallStatus: RECRUITING date: 2024-01-12 date: 2025-02 date: 2025-07 date: 2024-04-04 date: 2024-04-04 name: Rush University Medical Center class: OTHER briefSummary: Among young children, homelessness is an independent predictor of child developmental delay and disability, and children experiencing homelessness (CEH) are 2-4x more likely to demonstrate developmental delays compared to housed children. The purpose of this project is to evaluate an evidence-based model of caregiver coaching for CEH that screen positive for developmental delay. We will also evaluate the societal costs of the program, its preliminary efficacy, and the acceptability among caregivers and shelter staff. conditions: Developmental Delay studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: One group will receive the caregiver coaching intervention. primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Caregiver coaching measure: Parenting Sense of Competence Scale measure: Parenting Stress Scale measure: Mullen Scales of Early Learning measure: Maternal Behavior Responsivity Scale sex: ALL minimumAge: 12 Months maximumAge: 6 Years stdAges: CHILD facility: Rush University Medical Center status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Lauren Little role: CONTACT phone: 312-942-1759 email: lauren_little@rush.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06347653 id: 2023KT127 briefTitle: Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL) overallStatus: RECRUITING date: 2023-11-28 date: 2027-01-31 date: 2030-01-31 date: 2024-04-04 date: 2024-04-04 name: Peking University class: OTHER briefSummary: This study is conducted to evaluate the efficacy and safety of linperlisib combined with CHOP regimen followed by autologous hematopoietic stem cell transplantation and linperlisib monotherapy maintenance for newly diagnosed nTFHL patients. conditions: Nodal T-follicular Helper Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: linperlisib combined with CHOP regimen measure: progression-free survival measure: ORR measure: CR rate measure: Success rate of stem cell collection measure: overall survival (OS) measure: time to next anti-lymphoma treatment measure: adverse events sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bejing Cancer Hospital status: RECRUITING city: Beijing state: Beijing country: China name: PING WEI LIU, master role: CONTACT phone: 0086-13522796323 lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06347640 id: KingAbdullahUH2 briefTitle: Outcome of Pulp Revascularization of Necrotic Mature Permanent Teeth Using Platelet-rich Fibrin overallStatus: RECRUITING date: 2023-04-01 date: 2025-12-01 date: 2027-12-01 date: 2024-04-04 date: 2024-04-04 name: King Abdullah University Hospital class: OTHER name: Jordan University of Science and Technology briefSummary: Regenerative endodontic procedures are intended to replace damaged tooth structures, including dentine and root structures, in addition to cells of the pulp-dentine complex. This treatment modality have been tested on immature necrotic teeth because they are anticipated to have a greater chance of pulp tissue regeneration.
This clinical study will evaluate clinically and radiographically the effectiveness of PRF versus induced bleeding in treating mature necrotic teeth. Fifty patients with necrotic mature teeth with periapical lesions will be invited to participate in this study. Teeth will be treated using calcium hydroxide as intracanal medicament then using PRF (n=25) and blood clot (n=25) as scaffold. All teeth will be sealed coronally using NeoMTA Plus™. Treated teeth will be assessed clinically and radiographically using 2D periapical radiographs. The reported clinical and radiographic outcomes will be compared using SPSS. conditions: Pulp Revascularization studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized clinical trial primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: induced bleeding name: plasma rich fibrin measure: Complete healing measure: regain the pulp sensibility sex: ALL minimumAge: 12 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: Jordan University of Science and Technology status: RECRUITING city: Irbid zip: POBOX 3030 country: Jordan name: Lama A Awawdeh role: CONTACT phone: 0795412954 email: lawawdeh@hotmail.com lat: 32.55556 lon: 35.85 hasResults: False